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Abstract  Hairy  cell  leukemia  (HCL)  is  an uncommon  B-cell  lymphoid  neoplasia,  representing
2--3% of all  leukemias.  It  is more  common  in  men,  with  a  median  age  at diagnosis  of  52  years.
The hair-like  projections  on its  surface  are  its principal  characteristic.  Although  its  etiology  has
not been  established,  the  recent  gene  sequencing  of  HCL  identified  the  presence  of  the  BRAF
V600E mutation,  absent  in other  malignant  neoplasias  of  the  lymph  cells.  The  clinical  course  of
the disease  is  usually  indolent.  The  majority  of  patients  initially  present  weakness  and  fatigue,
pancytopenia  and  splenomegaly.
HCL must  be  distinguished  from  other  indolent  lymphoid  neoplasias  such  as  prolymphocytic
leukemia,  splenic  marginal  zone  lymphoma,  the  variant  of  HCL  (HCLv),  and  mantle  cell  lym-
phoma. Peripheral  blood  flow cytometer  is essential  for  the detection  of  CD11c,  CD19,  CD20,
CD22, CD25,  and  CD10,  as  well  as a  bone  marrow  aspirate  to  detect  immunophenotypes.  In  addi-
tion,  a  bone  biopsy  is  useful  to  perform  an  immunohistochemistry  analysis  for  TRAP,  DBA-44  and
A1 annexin.
Purine  analogues  remain  the  first  line  of  treatment.  However,  interferon  and  rituximab  are
a valid  option,  if  the ideal  treatment  is unavailable.  New  discoveries  in the  pathophysiology
of HCL  have  brought  the  creation  of  pharmaceuticals  with  distinct  therapeutic  targets.  These
pharmaceuticals  are  currently  undergoing  testing.
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Introduction
Hairy  cell leukemia  (HCL)  is  a  B-cell  lymphoid  neoplasia.
HCL  differentiates  from  other  B-cell  neoplasms  because  of
its  morphological,  immunophenotypic  and  molecular  char-
acteristics.  Its  main  characteristic  is  the  accumulation
of  monoclonal  B cells,  with  hair-like  projections  on  its
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surface,  mainly  found in peripheral  blood,  bone  marrow  and
the  spleen.  It was  described  in 1958  by  Bournoncle  et al.
However,  they  called  it  leukemic  reticuloendotheliosis.1 The
term  ‘‘hairy  cells’’  was  coined  in 1996  by  Schrek  et  al.2
Today  it  is  classified  by  the World  Health  Organization  as
a  B-cell  non-Hodgkin  lymphoma.3
Definition
HCL  is a  rare,  chronic,  lymphoproliferative  B-cells  disorder.
Its  main  characteristics  are the cytoplasmic  prolongations
which  give  the cells  a  hairy  aspect.
Etiology
Although  there  are  different  studies  showing  a link  between
exposure  to  certain  agents  and HCL,  its  etiology  has  not  been
clearly  established,  which  could  be  explained  due  to  its  low
incidence.  Amongst  the  agents  which  have  proven  a positive
link  are:  exposition  to  pesticides,4 herbicides,  mineral  oils,
working  as a  carpenter,  or  a farmer.4--7 Recently,  a positive
link  with  size  has  been  described,5 whereas  smoking  has  an
inverse  association,  especially  in  men.8 The  specific mecha-
nism  which  confers  the protection  is  unknown;  nevertheless,
smoking  has been  suggested  to  decrease  the severity  of
inflammatory  mechanisms9 and  that  nicotine  induces  apo-
ptosis  in  lymphocytes.10
Epidemiology
HCL  represents  2--3%  of  all leukemias.  There  are  600 new
cases  reported  per  year  in the U.S. (3.2 cases  per  million
inhabitants).  Median  age  at  diagnosis  is  52  years  old  and  it
is  more  common  in men  than  in women,  with  a  4:1  ratio;
with  a  higher  incidence  in the  white  population,  especially
among  Ashkenazi  Jews.3 In  Mexico,  HCL  represents  1.12%
of  all  leukemias.  However,  in  the  north  of  the country  it
represents  up  to  1.83%,  similar  to  the  information  from  the
U.S.11,12
Physiopathology
HCL  is a  chronic,  lymphoproliferative  B-cell  disorder.  How-
ever,  its  cells do  not  have  the  appearance  of any  B-cell
sub-population,  and  its  origin  has  been  a  matter  of  debate.
The  analysis  of  immunoglobulins  (Ig)  variable  regions  genes
is  a  tool used  to  discover  the lymphoid  cells’  clonal  origin.13
In  over  85%  of  cases,  we  are able  to  find  somatic  mutations
in  Ig  variable  regions  genes  of  HCL  cells,14,15 which  is  an
indication  that  the  cells  involved  have  passed  through  the
germinal  center  or  lymphoid  peripheral  organs.16 Approxi-
mately  40%  of  HCL  cells  co-express  multiple  clonally-related
Ig  isotypes.17
Evidence  suggests  an origin  post  germinal  center  in  mem-
ory  B-cells,  due  to  their genomic  expression  profile.18,19 The
origin  of  memory  B-cells is  compatible  with  HCL’s  lack  of
chromosomic  reciprocal  translocation.20 Absence  of CD27  is
typical  in  HCL.  This  represents  a point  against  the hypothe-
sis  of  its  origin  in memory  B-cells.21 However,  negative  CD27
memory  B-cells  have  been  observed.22 Since  lymph  node
affection  is  infrequent,  it  has  been  suggested  that  the HCL
origin  cell  is probably  located  in  the  bone  marrow  or  spleen,
since  those  are  usually  the  more  affected  places.  HCL  cells
show  an  expression  profile  similar  to  the  spleen’s  marginal
zone.23
HCL’s  characteristic  look is  due  to  the beta-actin  expres-
sion,  which  is  polymerized  to  F-actin,  located  in the cortical
cytoskeleton.24 PP52  phosphoprotein,  which  is  specific  for
leukocytes,  is  linked  to  F-actin  and is  responsible  for  bring-
ing  support  to  the hair-like  projections.25 On the other  hand,
HCL  gene  sequencing  recently  identified  the presence  of
a  BRAF V600E  mutation  in  almost  every  patient  with  the
disease,  absent  in other  B-cell  lymphoid  malignancies.26,27
BRAF  mutations  activate  the MAPK  pathway,  promoting
growth,  survival  and  HCL  cell  differentiation.28
Clinical  presentation and lab findings
The  disease’s  clinical  course  is  indolent.  Most patients
usually  present  weakness  and fatigue  as  the predominant
symptoms  during  the  onset  of  the disease.29 Sometimes,
there  is  a  history  of  repeated  infections.  The  fisical  exam-
ination  findings  are:  splenomegaly  in  96%, hepatomegaly  in
58%  and  lymphadenopathy  in only 35%.  These  swollen  lymph
nodes  are rarely  observed  in the  periphery;  nonetheless,
they  are generally  present  in  the abdomen  and  detected
by  imaging  studies.30
In an advanced  stage  of  the  disease  we  are  able  to
find  pain  in  the superior  left quadrant,  infections,  fever,
and  hemorrhages  and/or  weight  loss.  However,  this  is
uncommon  because  of  the  availability  and effectiveness  of
treatment.30,31 Clinical  manifestations  are  product  of hairy
cell  accumulation  in  the  spleen,  liver  and  bone  marrow
(Table  1).32
Respect  to  lab  studies,  it is  frequent  to  observe  anemia
in 85%, thrombocytopenia  in 60.80%  and leukopenia  in 60%
due  to  hypersplenism  and  bone  marrow  infiltration.30
Differential  diagnosis
HCL  must  be differentiated  from  other  indolent  lymphoid
malignancies  such as  prolymphocytic  leukemia,  splenic
marginal  zone  lymphoma,  mantle  cell  lymphoma  and  HCL
variant  (HCL-v).  The  last  one  occurs  in 10%  of  cases  with  a
median  age of  70 years,  and despite  the similarities  with
classic  hairy  cell leukemia,  they  diverge  in  the absence  of
the  CD25 and  CD123  immunophenotypic  markers.  Another
way  of making  a  differential  diagnosis  is  the lack  of  response
to  standard  HCL  treatment  and the  nonexistence  of  muta-
tions  of  the BRAF V600F  gene.30
Diagnostic methods
HCL  diagnosis is commonly  made  with  a  biopsy  and  bone
marrow  aspiration  combined  with  immunophenotypic  char-
acterization  through  flow  cytometry.33 It  is  important  to
point  out  that  this  pathology  is  usually  sub-diagnosed
and  requires  clinical  suspicion  and  the  use  of  the  proper
technology  to  solve  this problem.  As  previously  men-
tioned,  most  patients  (70--90%)  present  pancytopenia,  with
leucopenia  (<5  ×  109/L), anemia  (<10  g/dL), neutropenia
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Diagnosis
Hairy cell leukemia  
Symptomatic patient Asymptomatic patient 
Start treatment with purine
analogues.
- Cladribin
- Pentostatin
Unfavorable circumstances:
- Alpha interferon.
- Rituximab at a low or
normal dosage.
- Splenectomy     
Keep under surveillance
Lab test every 3 months for
the first year, and every 6
months after that.    
Evaluate rituximab 
Complete response 
or 
Partial response
Relapse 
Delayed (>2 years)
-Retreat with purine
analogues or with
rituximab or interferon.
Early (<2 years)
-Confirm the diagnosis
-BRAF-V600E inhibitors
-Inmunotoxins
-Ibrutinib
-Rituximab and interferon.
Algorithm  1 Chart  for  the  management  of  a  patient  with  hairy  cell  leukemia.
Table  1  Clinical  manifestations.
Spleen  Liver  Bone  marrow  Lymph  nodes
The  cells  accumulate  in  the
red pulp  and  atrophy  the
white  pulp.  They  later
form  the  so-called
‘‘pseudo-sinusoids’’
through  the  replacement
of the  endothelial  cells  of
the red  pulp  by  enhanced
vascular  channels,
contributing  to  anemia.
Here,  they accumulate
in  the  liver  sinusoids  as
well  as in  the portal
tract.  There  is  fibrosis  in
the  latter  due  to  the
abundant  hyaluronic
acid,  which  stimulates
the  hairy  cells  to
produce  fibronectin,
with  its  corresponding
fibrosis.
In  this  area,  there  is
extensive  production  of
fibrosis  and  suppression
of hematopoiesis.  The
key  factor  is the
interaction  of  the  hairy
cells  with  the hyaluronic
acid  of  the  extracellular
matrix,  generating
fibroblastic  growth
factors  (FGF)  and
stimulating  the  malign
cells  to  produce  and
secrete  fibronectin.
Generally,  absent  of  the
disease.  Lack  of
receptors  for  entry  of
hairy  cells.
(<1  ×  109/L),  monocytopenia  (<0.1  ×  109/L)  and  thrombocy-
topenia  (<100  × 109/L). Only  between  10%  and  20%  present
moderate  leukocytosis  (>10  ×  109/L). HCL  patients  dis-
play  elevated  IL-2R  (CD25)  serum  levels,  which  correlates
with  the  disease’s  degree  of  activity.34 Other  tests  which
should  be  considered  when making  the  diagnosis  are serum
immunoglobulin  levels,  as well  as  IgVH  gene and  BRAF
V600E somatic  mutations.32 Some  HCL  histopathologic  and
immunophenotypic  characteristics  are the  following:
• Lymphocyte  flow  cytometry  in peripheral  blood  or  bone
marrow  with  CD19,  CD20,  FMC7,  CD11c,  CD103,  CD25,
HC2,  CD22,  sIg,  CD79a  and CD123  expressions,  with  four
being  the  main  and  specific  markers:  CD11c,  CD103,  CD25
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Table  2  Criteria  to  begin  treatment.
1.  Symptomatic  splenomegaly
2. Cytopenia  involving  at  least  one  of  the  following:
-Hemoglobin  <10  g/dL
-Platelets  <100  ×  109/L
-Neutrophils  <1  × 109/L
3. Severe  infections
and  CD123.34 Commonly  negative  markers  are  CD5,  CD23,
CD10,  CD79b  and  CD27.32
• A  strong  expression  for  CD200  is  characteristic  of  HCL  and
may  be  useful  in the  diagnosis  of difficult  cases.34
• Bone  marrow  aspiration  with  a needle  may  be difficult
to  obtain  and  is  frequently  unproductive  or  ‘‘dry’’.  In  a
bone  marrow  biopsy,  we  can  observe  fibrosis,  with  a cellu-
lar  ‘‘fried-egg’’  look caused  by the  wide  spaces  between
nuclei  and  abundant  cytoplasm.  Immunohistochemistry
analyses  for CD20 and TRAP  (tartrate  resistant  acid  phos-
phatase),  DBA-4  and  annexin  A1  are conducted,  which  are
characteristically  positive.32
Andrulis  et  al. directed  a  study  where  the  efficiency  of
the  VE1  antibody  for  BRAF  V600E  detection  was  reported,
along  with  HCL  identification  in other  entities.  Moreover,  a
study  conducted  by  Uppal  et al. found a  sensitivity  of  88%
and  a  specificity  of 97%  to  detect  this  mutation  with  the
mentioned  antibody.34
Current treatment
HCL  regularly  has  an  indolent  evolution.  Waiting  and  observ-
ing  is  a  good  option  for  asymptomatic  patients,  since  early
treatment  does  not  offer  any  sort  of benefit  in  the  sur-
vival  rates  of these  cases.  Anyway, the progression  of  the
disease  in most  patients  will  lead  to  complications  as a
result  of  cytopenias  and splenomegaly;  i.e.  anemia,  hem-
orrhages,  recurrent  infections,  etc.  In  general  practice,
treatment  must  be  started  if any  of  the  criteria  listed  in
Table  2 occur.35 When  the decision  to  not  start  treatment
is taken, clinical  and laboratory  monitoring  should be  done
for  every  three  months  during  the  first  year  and  every
six  months  thereafter.35 HCL  treatment  is  not  considered
healing;  but  current  treatment  strategies  are capable  of
reaching  prolonged  remissions,  thus  increasing  global  sur-
vival  rates  (Algorithm  1).36--39
Purine  analogues
In  1960,  findings  showed  that  30%  of  children  with  severe
combined  immunodeficiency  syndrome  lacked  deaminase
adenosine  enzyme  (ADA).40 Furthermore,  they  discovered
that the  accumulation  of the  deoxyadenosine  triphosphate
form  was  responsible  for the  decrease  of  lymphocytes.41
Keeping  these observations  in mind,  medications  capable
of  binding  irreversibly  to  ADA  or  antagonizing  its  action
were  developed.  After  treatment  with  purine  analogues,
deoxyadenosine  triphosphate  accumulation  results  in rup-
ture  and  inhibition  of the  DNA  repair,  which  translates  into
cellular  apoptosis.42
Pentostatin
Also  known  as 2′-deoxycoformycin  (dcF),  a product  of  Strep-
tomyces  antibioticus  and  ADA  inhibitors,  first  introduced  in
1980  as  the  first  purine  analogues  for HCL  treatment.  In
Table  3,37,39,43,44 specific  studies  show  response  rates  to  pen-
tostatin.  Intravenous  use  of  pentostatin  at  a 4  mg/m2 ratio
once  every two  weeks  until  reaching  complete  response
was  approved  in the U.S.  Pentostatin  is  safe in patients
with  creatinine  lightening  >60 mL/min.  However,  a dosage
reduction  is  necessary  if this  depuration  is between  40  and
60  mL/min.32 Patient  hydration  with  1.5  L of  intravenous
solution  with  every pentostatin  cycle  is recommended.30
Global response  varies between  88%  and  96%, while
complete  response  is  between  44%  and 81%.  Flinn  et  al.
estimated  a  survival  rate  of  5 and 10  years  of 90%  and
81%,  respectively,  with  a mean  follow-up  duration  of  9.3
years.45 Pentostatin  is  generally  well-tolerated  and  the most
common  adverse  effects  are anemia,  thrombocytopenia
and  neutropenia.46 Still,  pentostatin  has been  reported  to
Table  3  Studies  on  the  effectiveness  of  pentostatin  in HCL  cases.
Study  Follow-up  Plan  %  CR  %  PR  %  GR  Outcome
Rafel  et  al.
(n =  78)
2.6  years  IV infusion
4 mg/m2/d
Every  2 weeks
72  16  88  Event-free  survival:
46 months
Else et  al.
(n  =  185)
10.8  years  IV infusion
4 mg/m2/d
Every  2 weeks
81  15  96  Global  survival  at  10
years:  98%
Ribeiro et  al.
(n  =  49)
3.2  years  IV infusion
4 mg/m2/d
Every  2 weeks
44  52  96  Global  survival:  86%
Maloisel et  al.
(n  =  238)
5.3  years  IV infusion
4 mg/m2/d
Every  2 weeks
79  17  96  Global  survival  at  5
years:  88.1%
Global  survival  at  10
years:  68.8%
RC: complete response, RP:  partial response, RG: global response.
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Table  4  Studies  on the  effectiveness  of cladribine  in  HCL  cases.
Study  Patients  Follow-up  Plan  %  CR  %  PR  %  GR  Outcome
Robak  (1999)  97  36  months  2  h  infusion
IV  0.12  mg/kg/d
5 days
77.3  18.6  95.9  Progression-free
survival:  37.4  months
Rosenberg (2014)  83  NA  Continuous  infusion
IV  0.1  mg/kg/d
7  days
88  12  100  Average  global  survival:
231  months
Goodman (2003)  207  7 years  Continuous  infusion
IV  0.1  mg/kg/d
7  days
95  5 100  Global  survival  at  108
months:  97%
Chadha (2005) 86  9.7  years Continuous  infusion
IV  0.1  mg/kg/d
7  days
79  21  100  Global  survival  at  12
years:  87%
RC: complete response, RP: partial response, RG: global response.
decline  CD4+  and  CD8+  lymphocyte  counts  significantly,
which  could  increase  secondary  malignancies  and  incidence
of  infections.47,48
Cladribine
It  is  known  as  2-chlorodeoxyadenosine  (CdA).  In  Table  4,49--52
studies  indicate  its effectiveness.  The  most used  scheme
consists  of  administering  0.1  mg/kg/day  in a  continuous
infusion  for  7 days.  In a non-randomized  study,  there  was
evidence  proving  that  there  was  no  statistically  significant
difference  in the  response  and toxicity  ranges  between
infusions  (24  h  and  2 h).53 Another  randomized  study  com-
pared  daily  versus  weekly  cladribine  administration;  there
were  no  significant  findings  in response,  survival,  global  and
toxicity  rates.54 A  different  study  showed  that  the  weekly
program  reduced  the risk  of  infections.55 One  of  the advan-
tages  of  subcutaneous  administration  is  the  fact that  in most
cases  it  does  not  require  hospitalization.  0.14  mg/day  for 5
days  has  a 95%  response  rate,56 similar  to  the intravenous
administration.  Weekly  subcutaneous  programs  have  simi-
lar  response  and  toxicity  rates  as  daily  ones.57 With  just
one  cladribine  cycle,  a global  response  up  to  100% can
be  obtained,  and  total  response  rates  differ from  77%  to
95%.49--52 Jehn  et  al.  reported  a global  survival  at 12  years  of
79%.36 In general,  cladribine  is well-tolerated,  with  cytope-
nias  and  fever  being  the  most common  adverse  effects.
Until  now,  there  are  no  randomized  prospective  studies
comparing  pentostatin  versus  cladribine,  in part  because
of  the  great  efficiency  of  both  drugs  and  due  to  low  HCL
incidence.  Even  so, there  are  retrospective  studies  proving
the  fact  that  both  drugs  have  a similar  efficacy,  in terms  of
complete  response  and free-of-disease  survival.
Other treatments
Purine  analogues  remain  the first  line  of treatment  but  new
discoveries  regarding  HCL  pathophysiology  have  led to  the
creation  of  drugs  with  different  therapeutic  targets.  These
drugs  are  under  research  and  some  have  shown  promising
results.
Rituximab
Since  HCL  is a B-cell  malignancy,  it  is  logical  to use  a mono-
clonal  antibody  against  CD20,  such as  rituximab.  Employed
as  a stand-alone  drug,  rituximab  may  reach  total  response
rates  of 10--54%  in  patients  with  an  HCL  relapse,  at a
375  mg/m2 dosage  once  a week  for  4--8  weeks.58,59 Else  et  al.
retrospectively  reviewed  18  patients  who  were  treated  with
purine  analogues  in  combination  with  rituximab  as  a  second
line  of treatment,  after being  treated  with  purine  analogues
as  single  agents.  All  patients  responded,  with  a  complete
response  rate  of  89%.60
Rituximab  at 375 mg/m2 per  week  for  8 weeks  as  initial
therapy  after  administrating  5.6  mg/m2 cladribine  via  2-h  IV
infusion  for  5 days  generates  a  total  response  of  100%.61 In
special  or  unfavorable  situations,  100  mg  of  rituximab  per
week  may  be  utilized  for  4--6  weeks.  This  is less  expensive
and  is  usually  effective,  especially  when is  combined  with
interferon.
While  purine  analogues  may  not  be capable  of elimi-
nating  HCL,  since  minimal  residual  disease  (MRD)  detected
after  cladribine  administration  is  always  strongly  CD20+,
MRD eradication  may  be obtained  using  rituximab.  Rivandi
et  al. proved  in  a preliminary  study  that  rituximab  at  con-
ventional  doses  for a  period  of  8  weeks  performs  with  great
activity,  eliminating  MRD in 13  patients,  when it is  used  4
weeks  after  the  administration  of cladribine.62
Vemurafenib
As  described  earlier,  BRAF V600E  mutation  is  the  genetic
key  in HCL.  Therefore,  it  is  a therapeutic  target  which has
been  studied  in  recent  years.  Vemurafenib  is  a BRAF  V600E
oral  inhibitor.  Tiacci  et al. conducted  a  study  to  measure
Vemurafenib  activity  and  safety in patients  with  HLC  who
relapsed  after  treatment  with  purine  analogues  or  who  were
refractory  to  the  administration  of purine  analogues.  Global
response  rate  was  96%  and complete  response  rate  was  35%,
with  a  relapse-free  survival  mean  of 19 months. The  adverse
effects  were  rash,  arthralgia  and arthritis.63
Since  a positive  relation  has  been  observed  between
the  use  of Vemurafenib  and  the onset  of dermatological
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malignancies,  frequent  explorations  of  the  skin  are  recom-
mended.
Ibrutinib
A  selective  and  irreversible  inhibitor  of  the Burton’s  tyrosine
kinase  intervenes  in the  B-cell  signaling  pathway.64 An  ibru-
tinib  clinical  assay  in  patients  with  HCL  relapse  has  recently
begun.  Preliminary  efficacy  and  safety  data  show  adverse
effects  such  as  eruptions,  diarrhea  and arthralgia.  This  clin-
ical  assay  is  currently  taking  place  in several  centers  in the
U.S.  (NCT01841723).
Immunotoxins
In  order  to increase  monoclonal  antibody  cytotoxicity,  tech-
niques  that  facilitate  the production  of  antibody--toxin
or  antibody--drug  conjugates  have  been  created.  An
immunotoxin  is  the fusion  between  a bacterial  toxin  (i.e.
Pseudomonas  exotoxin  or  diphtheria)  and the variable  frac-
tion  of  a  monoclonal  antibody,  whose  specific  target  is  found
on  the  surface  of  neoplastic  cells  like CD25 or  CD22.  This
toxin  is  released  in the  neoplastic  cell’s  interior  and  inter-
feres  with  protein  synthesis.65
BL22  is  an  immunotoxin  against  CD22 fused  with  a  trun-
cated  shape  of the P.  exotoxin  PE38.  In  a phase  II clinical
assay,  BL22  was  tested  in  36  HCL  relapse  or  refractory
disease  cases.  After  a  cycle  (40  mg/kg  every two  days,
three  doses),  complete  response  rate  was  25%  and  global
response  rate  was  50%.  These  responses  improved  to  a total
response  rate  of 47%  and a  global  response  rate  of  72%
after  retreatment  (only  in patients  with  cytopenias).  Two
patients  developed  uremic  hemolytic  syndrome  without  the
need  to  recur  to  plasmapheresis.66 Subsequently,  moxetu-
momab  pasudotox  was  developed  as  a modified  version  of
BL22  with  a higher  affinity  and cytotoxicity.  In  a  phase  I
assay,  which  included  28  patients  with  HCL  relapse  and  resis-
tance,  a  global  response  rate  of  86%  was  obtained,  including
a  sustained  complete  response  rate  in 46%  of  patients.67
Therapeutic options in  unfavorable
circumstances
Even though  HCL  is treated  in most  developed  countries  with
cladribine  and  pentostatin,  it  is  a fact  that these drugs  are
not  only  expensive,  they  are  not available  in Mexico  and in
many  countries  with  limited  resources.  So, in these types
of  circumstances,  there  are other  affordable  therapeutic
options  with  favorable  results
Interferon  alpha  for  HCL  patient  treatment  was  first
introduced  in 1984.  Today,  its  use  is  limited,  mainly  due  to
purine  analogues’  great  effectiveness.  On the other  hand,
in  countries  with  low economic  resources,  it is  an inex-
pensive  option  and  one  which  has  proved  similar  results  to
those  of  cladribine  in terms  of global  survival.  Ruiz-Delgado
et  al.  conducted  a comparative  study  between  interferon
alpha  (n  = 18)  and  cladribine  (n  = 11), where  the  difference
in  global  survival  between  both  groups  was  not  statistically
significant;  94%  at 217  months  in  the interferon  group  and
91%  at  133  months  in  the cladribine  group.68 In  a  study
conducted  in  our center,  nine  HCL  patients  received  three
IFN  mega-units  three  times  a  week  for  12  weeks,  subse-
quently  they  received  treatment  once  again  for 8 weeks
when  there  was  a  leukemia  reactivation  or after  10  months
of  observation  each year.  All  patients  had  a  hematological
remission  before  12  weeks  of treatment.  This  therapeu-
tic  option  is  cheaper,  effective  and  comparable  to  other
forms  of  therapy  with  IFN  in the  treatment  and maintenance
of  patients  with  this  type of  leukemia.69 It  is  possible  to
combine  interferon  with  rituximab  without  increasing  toxic
effects  and  improving  effectiveness.
Splenectomy  was  the first  intervention  that  significantly
changed  the survival  in patients.  Today,  it  is  rarely  used.
It  may  be recommended  in patients  with  painful  massive
splenomegaly  (>10  cm under  the costal  edge)  and  with  mini-
mal  infiltration  of the  bone  marrow,  or  in patients  refractory
to  treatment  with  interferon  and  purine  analogues.33 Retro-
spective  studies  show a complete  response  rate  of  40--62%,
and  a mean  survival  rate  at  5  years  up  to  68%.70,71 Lad  et  al.
published  a  retrospective  study,  including  24  patients  with
an  HCL  diagnosis,  they  were  divided  into  two  groups:  17
patients  received  cladribine  and  7 were  splenectomized.
75%  of patients  in the splenectomy  group  showed  total
remission,  94%  did so  in the  cladribine  group.  An  interesting
finding  when  comparing  both  groups  was  that  no  statistically
significant  differences  were observed  regarding  leukemia-
free  survival  and global  survival.72
Prognosis
Survival  time  in  patients  after  diagnosis  was  4  years  before
a  treatment  was  known,  due  to  complications  derived  from
cytopenias,  including  hemorrhages  and  infections.  There-
after,  with  splenectomy  as  a  first  line  treatment,  there  was
a  complete  response  of  40--62%  and  a survival  rate  of  5  years
at  61--68%.  Then, alfa  interferon  was  utilized  as  the  first drug
with  benefits  in  the  treatment  of  HCL.  Still its  full response
rate  was  low, at  10%.73
Today,  with  purine  analogues  (pentostatin  and  cladrib-
ine), complete  response  is  induced  up to  80%  of  patients
with  a median  survival  of  10  years.  Global  response  rates
are  96--100%  with  a complete  response  rate  of 80%  and  a
survival  rate  of  10  years  ranging  between  85%  and  100%.74
Despite  that, a  significant  proportion  of patients  with  HCL
fail  in  their  response  to  treatment  or  become  resistant.  Up
to  48%  of  patients  relapse  in  the following  15  years.75 The
future  of HCL  patients  is  very  favorable.  The  challenge  is
to  identify  this malignancy  as  early  as  possible  and  treat  it
properly  using  available  resources.
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